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Development of new method to 
enrich human iPSC-derived renal 
progenitors using cell surface 
markers
Azusa Hoshina1, Tatsuya Kawamoto2, Shin-Ichi Sueta1, Shin-Ichi Mae1, Toshikazu Araoka1, 
Hiromi Tanaka1, Yasunori Sato3, Yukiko Yamagishi  2 & Kenji Osafune  1
Cell therapy using renal progenitors differentiated from human embryonic stem cells (hESCs) or induced 
pluripotent stem cells (hiPSCs) has the potential to significantly reduce the number of patients receiving 
dialysis therapy. However, the differentiation cultures may contain undifferentiated or undesired 
cell types that cause unwanted side effects, such as neoplastic formation, when transplanted into a 
body. Moreover, the hESCs/iPSCs are often genetically modified in order to isolate the derived renal 
progenitors, hampering clinical applications. To establish an isolation method for renal progenitors 
induced from hESCs/iPSCs without genetic modifications, we screened antibodies against cell surface 
markers. We identified the combination of four markers, CD9−CD140a+CD140b+CD271+, which could 
enrich OSR1+SIX2+ renal progenitors. Furthermore, these isolated cells ameliorated renal injury in an 
acute kidney injury (AKI) mouse model when used for cell therapy. These cells could contribute to the 
development of hiPSC-based cell therapy and disease modeling against kidney diseases.
Dialysis therapy and renal transplantation are currently the only effective options to treat stage 5 chronic kidney 
disease (CKD). Renal transplantation is effective but uncommon because of a lack of donors, and dialysis therapy 
reduces patient quality of life (QOL). Further, an increasing number of CKD patients is causing growing eco-
nomic burden to health care systems1. In order to solve these problems, regenerative medicine strategies using 
embryonic renal progenitors differentiated from human embryonic stem cells (hESCs) or induced pluripotent 
stem cells (hiPSCs) have attracted attention.
Differentiation methods for renal progenitor cells from hESCs/iPSCs have mimicked normal kidney devel-
opment2,3. The mammalian adult kidney metanephros is formed at the posterior end of intermediate mesoderm 
(IM)4. A nuclear transcription factor, Odd-skipped related 1 (Osr1), is one of the earliest markers specific for the 
IM, whose expression starts early (embryonic day (E) 7.5)5. Osr1 knockout mice lack renal structures due to the 
failure to form the IM6,7. A homeodomain transcriptional regulator, Six2, is expressed in cap mesenchyme (CM) 
derived from metanephric mesenchyme (MM). Cells expressing Six2 represent a multipotent, self-renewing 
progenitor population that can generate all cell types of the main body of the nephron8,9. Inactivation of Six2 
results in premature and ectopic renal vesicles, leading to a reduced number of nephron and to renal hypoplasia10. 
Overall, in contemporary models, Osr1 and Six2 are required to maintain renal progenitor cells during kidney 
organogenesis11.
Several groups have reported renal progenitor induction from hESCs/iPSCs12–15. Taguchi et al. demonstrated 
the induction of SIX2+ renal progenitor cells from hiPSCs by aggregate cultures, and these renal progenitor 
cells exhibited tubulogenesis and podocyte formation when cocultured with mouse embryonic spinal cords12. 
Takasato et al. produced nephron structures from hiPSCs by organoid cultures and induced SIX2+ renal pro-
genitor cells during the induction13. Morizane et al. reported the induction of SIX2+ renal progenitor cells from 
hiPSCs by 2D cultures, and that the cells went on to form nephron structures after being transferred to 3D culture 
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conditions14. They also showed an elevation of OSR1 mRNA expression in the induced SIX2+ renal progenitor 
cells by qRT-PCR.
Despite the above success, the induced cells are not suitable for clinical applications, because the induction 
rates of SIX2+ renal progenitors suggested that other lineage cells as well as undifferentiated cells might be mixed 
in the differentiation cultures. These contaminating cells could cause neoplastic formations and other unexpected 
side effects. Previously, we reported a protocol for differentiating hiPSCs into OSR1+SIX2+ renal progenitors15. 
Although the induction rate was low at around 40%, the progenitor cells showed therapeutic effects by trans-
plantation into the renal subcapsule of acute kidney injury (AKI) model mice. However, because both progenitor 
markers are nuclear transcriptional factors, the hiPSCs were genetically modified to express OSR1-green fluo-
rescent protein (GFP) and SIX2-tdTomato for isolation of the cells, meaning the cells cannot be used for clinical 
applications.
Here, we developed an isolation method for renal progenitors by flow cytometry that avoids genome editing 
and uses monoclonal antibodies against cell surface markers. We screened monoclonal antibodies against cell 
surface markers that isolate OSR1+SIX2+ renal progenitors by flow cytometry and identified three positive and 
three negative selection markers. We then identified the combination of CD9−CD140a+CD140b+CD271+ as sur-
face markers for renal progenitors derived from hiPSCs that have therapeutic potential for AKI in mice. The iso-
lation method established in this study can provide a tool for efficient and safe cell therapy and disease modeling.
Results
Screening selectable markers to concentrate OSR1+SIX2+ cells differentiated from hiPSCs. 
The screening of monoclonal antibodies against cell surface markers was performed on the differentiated cells 
around day 28 of our differentiation protocol15 using commercially available screening panels that included 242 
antibodies and flow cytometry. To search selectable surface markers for OSR1+SIX2+ cells in whole differentiated 
cells without purification, we used an OSR1-GFP/SIX2-tdTomato double knock-in hiPSC line we had previ-
ously established from a fibroblast-derived hiPSC line, 201B715. First, we picked up three cell surface markers 
(CD140a, CD140b and CD271) that could detect OSR1+ and SIX2+ cells (Fig. 1A), but not undifferentiated 
hiPSCs (Fig. 1B). We next picked up an additional three cell surface markers (CD9, CD55 and CD326) that were 
negatively correlated with OSR1+ and SIX2+ cells (Fig. 1C) and expressed in hiPSCs (Fig. 1D), enabling us to 
exclude undifferentiated cells from the differentiated cultures.
To efficiently concentrate OSR1+SIX2+ cells, we tested various combinations of these selectable markers 
(Table S1). As a result, we chose the combination of CD9, CD140a, CD140b and CD271 as the most efficient to 
obtain OSR1+SIX2+ cells (Figs 1E and S1). Fractionated cells by CD9−CD140a+CD140b+CD271+ were isolated 
and analyzed to confirm the enrichment of OSR1+SIX2+ cells with these markers by flow cytometry. The percent-
age of CD9−CD140a+CD140b+CD271+ cells in each fraction was as follows: OSR1−SIX2− fraction, 7.1 ± 1.5% 
(n = 3); OSR1+SIX2− fraction, 21.1 ± 0.7% (n = 3); OSR1−SIX2+ fraction, 7.9 ± 1.6% (n = 3); and OSR1+SIX2+ 
fraction, 63.8 ± 3.3% (n = 3). Thus, OSR1+SIX2+ cells compared with whole differentiated cells were markedly 
enriched in CD9−CD140a+CD140b+CD271+ cells (Fig. 1F).
We next examined these cell surface markers on cells differentiated from another hiPSC line, 585A1, which 
was derived from the peripheral blood mononuclear cells of a healthy Japanese donor16. Because CD140a+, 
CD140b+ and CD271+ cells were induced at low efficiency (7.6 ± 1.4%, 11.2 ± 1.9% and 10.7 ± 2.4%, respectively 
(n = 3)), the induction efficiency of CD9−CD140a+CD140b+CD271+ cells was low at 5.0 ± 1.2% (n = 3) (Fig. S2). 
Nevertheless, we could obtain CD9−CD140a+CD140b+CD271+ renal progenitors from 585A1 cells.
Isolation of hiPSC-derived renal progenitors using cell surface markers. In order to determine 
whether the hiPSC-derived CD9−CD140a+CD140b+CD271+ cells show characteristics of embryonic renal pro-
genitors, the cells were isolated with a flow cytometer. We observed that the ratio of OSR1 (GFP)+, SIX2+ and 
HOXD11+ cells after isolation was substantially increased compared with that before isolation by immunos-
taining (Fig. 2A,B). We then analyzed the gene expression levels of OSR1 and SIX2 and found an enrichment of 
CD9−CD140a+CD140b+CD271+ cells compared with unsorted cells (Fig. 2C). We also found enrichment in the 
expression levels of other renal progenitor markers such as CITED1, ITGA8, CDH11, HOXA11 and HOXD11 
compared with unsorted cells. In contrast, we did not observe a significant increase in the expression levels of 
EYA1, WT1 or SALL1. Because these genes are expressed during the IM and early MM stages4, we assumed that 
OSR1+SIX2− cells included in the unsorted cells might express these markers and explain the absence of enrich-
ment after isolation. As expected, the expression levels of undifferentiated markers, such as NANOG and OCT4, 
were lower after isolation (Fig. 2D). We also confirmed that the isolated cells did not express markers for other 
mesodermal, endodermal and ectodermal lineage tissues (Fig. S3). These results indicate that the combination of 
CD9, CD140a, CD140b and CD271 can enrich renal progenitor cells differentiated from hiPSCs.
Next, we examined our cell surface marker combination on cells differentiated from 585A1 by using another 
differentiation method for renal progenitors12. In this case, the induction rate of CD9+ cells was very low (0.9 ± 0.1%, 
n = 3) and cells positively stained with the other three surface markers (CD140a, CD140b and CD271) were vari-
able among the experiments (Table S2). Because CD271+ cells were less efficiently induced among the CD140a+, 
CD140b+ and CD271+ cell populations, we isolated the CD140a+CD140b+ cell population by flow cytometry sort-
ing and confirmed that SIX2+ cells were enriched after isolation with these two cell surface markers (Fig. S4).
We previously showed that OSR1+SIX2+ cells differentiated from hiPSCs by our differentiation method 
contributed to renal lineage cells and mainly formed 3D proximal renal tubule-like structures, but not 
glomeruli-like structures, in vitro15. We also assessed the developmental potential of hiPSC-derived 
CD9−CD140a+CD140b+CD271+ cells isolated on day 28 by a previously reported organ culture procedure17 (Fig. 
S5A). As a result, the aggregates developed tubular structures consisting of cells positive for a proximal renal tubule 
marker, Lotus tetragonolobus lectin (LTL), and for a distal renal tubule marker, E-cadherin (Fig. S5B,C). However, 
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we did not find glomeruli-like structures positively stained for NEPHRIN, PODOCIN, WT1 or PODOCALYXIN 
in more than 10 examinations (data not shown). These results suggest that CD9−CD140a+CD140b+CD271+ cells 
generated from hiPSCs have similar developmental potential to hiPSC-derived OSR1+SIX2+ renal progenitors.
Figure 1. Flow cytometric analysis and characterization of surface markers that can concentrate OSR1+SIX2+ 
cells from differentiation culture. (A) Positive selectable markers that detect OSR1+ and SIX2+ cells. (B) 
These positive selectable markers do not detect undifferentiated hiPSCs. (C) Negative selectable markers that 
are negatively correlated with OSR1+ or SIX2+ cells. (D) These negative selectable markers are expressed in 
undifferentiated hiPSCs. (E) Differentiated cells fractioned with antibodies directed against CD9, CD140a, 
CD140b and CD271. (F) Flow cytometric analysis of undifferentiated hiPSCs (left), whole differentiated 
cells before isolation (center) and isolated cells fractioned with gates of CD9−CD140a+, CD9−CD140b+ 
and CD9−CD271+ (right) for OSR1 and SIX2. Results of the antibody screening are shown in (A) and (C). 
Representative data from at least three independent experiments are shown in (B), (D) and (E). The data from 
three independent experiments are presented as the mean ± SE (n = 3) in (F).
www.nature.com/scientificreports/
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Transplantation of hiPSC-derived CD9−CD140a+CD140b+CD271+ renal progenitors ame-
liorates AKI in mice. In order to examine the therapeutic potential of hiPSC-derived renal progeni-
tors isolated with the combination of cell surface markers identified in this study, we transplanted aggregates 
Figure 2. The expression of renal lineage markers in CD9−CD140a+CD140b+CD271+ cells isolated from 
hiPSC differentiation culture. (A) Anti-GFP (OSR1), SIX2 and HOXD11 immunostaining images of the cells 
before isolation (upper panels) and isolated CD9−CD140a+CD140b+CD271+ cells (lower panels) on culture 
days 28 (SIX2) and 30 (OSR1 and HOXD11). Representative images from three independent experiments 
are shown. Scale bars, 100 µm. (B) The induction rates of SIX2+ cells in day 28 cells before and after isolation. 
The data from three randomly chosen fields are presented as the mean ± SE (n = 3). (C,D) qRT-PCR analyses 
of gene expressions in day 28 cells before and after isolation for markers of nephron progenitors (C) and 
undifferentiated cells (D). The data from three independent experiments are presented as the mean ± SE (n = 3). 
GAPDH was used as an internal control, and the relative expression levels were normalized to those of day 28 
cells before isolation (C) and hiPSCs (D). ITGA8, integrin alpha 8; CDH11, cadherin 11.
www.nature.com/scientificreports/
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of hiPSC-derived CD9−CD140a+CD140b+CD271+ cells isolated on day 28 into kidney subcapsules of AKI 
mouse models induced with ischemia reperfusion (I/R) injury just after the injury. A renal functional parameter, 
blood urea nitrogen (BUN) level, was significantly lower in the mouse group transplanted with hiPSC-derived 
CD9−CD140a+CD140b+CD271+ cells than in the control mouse group injected with saline from 2 to 12 days 
after I/R. Another parameter, serum creatinine (Cre) level, was also significantly lower in the transplantation 
group two days after I/R (Fig. 3A). We also compared the therapeutic potential of unsorted cells before iso-
lation and isolated CD9−CD140a+CD140b+CD271+ cells, finding that the therapeutic effects of unsorted 
cells were unstable (Fig. S6). In addition, the serum Cre level on day 2 after I/R was significantly lower 
when isolated CD9−CD140a+CD140b+CD271+ cells were transplanted compared with the unsorted cells. 
Similarly, the BUN level on day 2 was considerably lower, albeit not significantly, with the transplantation of 
CD9−CD140a+CD140b+CD271+ cells (Fig. S6).
Histological analyses revealed that the areas of kidney injury with tubular dilatation and loss of tubular bor-
ders were significantly smaller in the mouse group treated with hiPSC-derived CD9−CD140a+CD140b+CD271+ 
cells than in the saline group (Fig. 3B,C). The other two kidney injury findings, tubular necrosis and urinary 
cast, were not significantly but considerably smaller in the transplantation group than in the saline group. These 
results indicate that the transplantation of hiPSC-derived CD9−CD140a+CD140b+CD271+ cells ameliorates AKI 
in mice.
Transplantation of hiPSC-derived CD9−CD140a+CD140b+CD271+ renal progenitors prevents 
kidney fibrosis after AKI. The interstitial fibrosis occurring after AKI is related to renal prognosis18. 
Histological analysis by anti-α-smooth muscle actin immunostaining revealed that the fibrosis areas were signifi-
cantly smaller in the transplanted group (Fig. 4A,B), which is consistent with the results of the qRT-PCR analysis 
for α-Sma expression levels (Fig. 4C). The areas of interstitial fibrosis evaluated by Masson’s trichrome and Sirius 
red stainings as well as the expression levels of other fibrosis markers including Fsp1 and Col4a1 were not signifi-
cantly but considerably smaller in the transplantation group than in the saline group (Fig. 4). These results suggest 
that the transplantation of hiPSC-derived CD9−CD140a+CD140b+CD271+ cells may prevent renal fibrosis after 
AKI and improve kidney prognosis.
Discussion
Cell therapy using renal progenitors derived from hESCs/iPSCs is an expected effective treatment for kidney 
disease. To realize this potential, the removal of contamination by other lineage cells and undifferentiated cells is 
imperative, as these cells risk neoplastic formations and other unwanted side effects. To solve this problem, the 
development of an isolation method for renal progenitors by using cell surface markers is required. In the present 
study, we identified the combination of CD9−CD140a+CD140b+CD271+ as most efficient for enriching renal 
progenitors derived from hiPSCs. Several studies have already reported cell surface markers to isolate clinically 
useful cell types induced from hESCs/iPSCs, such as cardiomyocytes19,20, midbrain dopaminergic progenitor 
cells21, neural stem cells, glia and neurons22, pancreatic progenitor cells23 and liver progenitor cells24. However, 
cell surface markers for renal progenitors induced from hESCs/iPSCs have not yet been reported. After iso-
lation using the combination of cell surface markers established in this study, we found increased expression 
levels of renal progenitor markers and decreased marker expressions for other lineages and undifferentiated cells. 
Furthermore, we demonstrated that CD9−CD140a+CD140b+CD271+ cells derived from hiPSCs have therapeutic 
potential against AKI.
The purity of OSR1+SIX2+ renal progenitors by our isolation method is not high (63.8 ± 3.3%, n = 3) and 
should be improved in the future. However, our method can enrich renal progenitors with therapeutic poten-
tial on AKI that are differentiated from hESC/iPSC lines without genome editing and can remove any undif-
ferentiated cells. Using our previously reported differentiation protocol15, in the present study we generated 
CD9−CD140a+CD140b+CD271+ cells from 585A1 cells at low induction efficiency around day 28. One possible 
explanation for the efficiency differences is that surface marker expressions could be temporally dependent on 
the differentiation culture. Another possibility is that the differentiation potentials toward specific lineages are 
different among hESC/iPSC lines25–28. Indeed, Morizane et al. demonstrated such substantial differences in the 
differentiation potential to nephron progenitors14. On the other hand, when we differentiated 585A1 cells into 
nephron progenitors by using another differentiation protocol12, the induction rate of CD9+ or CD271+ cells was 
very low (Table S2). Different differentiation protocols may require some modifications to acquire renal progen-
itors of the same character. Future studies are necessary to identify the time course of the purification and the 
combination of cell surface markers for each cell line or differentiation method.
The surface markers identified in this study were expressed during kidney development. CD140a, also known 
as platelet-derived growth factor receptor α (PDGFRα), is expressed in metanephric interstitium and vascular 
arcades that course through the blastema in human fetal kidney29. Mice deficient of PDGFRα show a lack of 
interstitial mesenchyme in the cortex of developing kidney30. CD140b, also known as PDGFRβ, is also expressed 
throughout the interstitium in human fetal kidney31. PDGFRβ-expressing cells are located in the cleft of comma- 
and S-shaped bodies and present a mesangial distribution at later developmental stages31–33. PDGFRβ-deficient 
mice are hemorrhagic, thrombocytopenic and severely anemic, exhibiting an abnormal glomerular phenotype 
characterized by a total lack of mesangial cells, and die at or shortly before birth34. OSR1+SIX2+ renal progen-
itors show differentiation potential mainly to renal tubules15, while both PDGFRα and PDGFRβ are expressed 
in the interstitial cells of developing kidneys, which seems an inconsistent finding. Our result is also inconsist-
ent with the findings of a previous report that showed colony-forming renal progenitors can be enriched in 
the Osr1+Itga8+Pdgfra− fraction of mouse embryonic kidneys and that the Itga8+Pdgfra− fraction contains 
Six2+ cells12. One possible explanation for these discrepancies is species differences between humans and mice. 
Another possibility is the difference in developmental stages. Because both nephron progenitors and interstitial 
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cells develop from MM, OSR1+SIX2+ cells in the early developmental stage may contain MM cells that express 
PDGFRα and PDGFRβ. OSR1+SIX2+ cells induced by our induction protocol may be more immature than 
the colony-forming renal progenitors reported by Taguchi et al.12. CD271, also known as nerve growth factor 
Figure 3. Cell therapy using hiPSC-derived CD9−CD140a+CD140b+CD271+ cells for acute kidney injury 
(AKI) model mice. (A) Time course analysis of blood urea nitrogen (BUN, left) and serum creatinine (Cre, 
right) levels in ischemia/reperfusion (I/R) AKI mice that received a renal subcapsular transplantation of hiPSC-
derived CD9−CD140a+CD140b+CD271+ cells (n = 4, iPSC-RPs, diamond) or saline injection (n = 4, square). 
Statistical significance: ***P < 0.001 vs. saline, **P < 0.01 vs. saline and *P < 0.05 vs. saline after multiple testing 
adjustment. Least square means and 95% confidence intervals were estimated according to the mixed effects model 
for repeated measures. (B) Representative section images of the host mouse kidney samples that received saline 
injection (upper panels) or transplantation of iPSC-RPs (lower panels) on day 12 after I/R and transplantation. 
Tubular necrosis, urinary cast, tubular dilatation and loss of tubular borders can be seen in each treatment group. 
The arrows indicate representative areas of each finding. Scale bars, 100 µm. (C) Histological intensity scores of 
tubular necrosis, urinary cast, tubular dilatation and loss of tubular borders in host kidneys on day 12 after I/R 
injury (n = 4). Statistical significance: *P < 0.05 vs. saline after multiple testing adjustment. BUN, blood urea 
nitrogen; Cre, creatinine; HE, Hematoxylin and eosin; PAS, periodic acid-Schiff; NS, not significant.
www.nature.com/scientificreports/
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receptor (NGFR), is also expressed in developing kidneys. In rat fetal kidney, Sariola et al. demonstrated that 
NGFR is localized in MM at E13 and that the expression is strong in S-shaped bodies and ceases a few days 
after birth35. They also reported that anti-sense oligonucleotide blockage of NGFR expression inhibited kidney 
Figure 4. The evaluation of kidney fibrosis after cell therapy using hiPSC-derived CD9−CD140a+CD140b+CD271+ 
cells in mouse acute kidney injury (AKI) models (A) Representative images of host mouse kidney sections stained 
with anti-alpha smooth muscle actin (α-SMA) immunostaining and Masson’s trichrome (MT) and Sirius red (SR) 
stainings in saline- (upper panels) or CD9−CD140a+CD140b+CD271+ cell (iPSC-RP, lower panels)-treated groups. 
The boxed areas are magnified and displayed in the right panels. Scale bars, 500 µm in the panel to the farthest left 
and 100 µm in the others. (B) Quantitative analyses of kidney fibrosis areas by anti-α-SMA immunostaining and MT 
and SR stainings in the host kidneys on day 12 after I/R injury (n = 4). Statistical significance: *P < 0.05 vs. saline after 
multiple testing adjustment. (C) qRT-PCR analyses of gene expression in the host kidneys on day 12 after I/R injury 
for the markers of kidney fibrosis (n = 4). Statistical significance: *P < 0.05 vs. saline after multiple testing adjustment. 
Fsp1, Fibroblast-specific protein 1; Col4a1, alpha-1 subunit of collagen type IV, NS, not significant.
www.nature.com/scientificreports/
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morphogenesis. Li et al. recently demonstrated that the SIX2+ cell population from human fetal kidneys was 
enriched in the NGFR+EpCAM− fraction17. Consistently, we also identified EpCAM (CD326) as a negative selec-
tion marker in our screening. CD9, also known as Multidrug resistance-associated protein 1 (MRP1), is expressed 
in human developing kidneys. In human fetal kidney, Konieczna et al. showed that MRP1 expression is nega-
tive in the mesenchyme but weakly positive in the metanephric blastema and becomes stronger at the stages of 
comma- and S-shaped bodies36.
Harari-Steinberg et al. previously demonstrated that NCAM1 (CD56) can isolate renal progenitor cells from 
human fetal kidneys37. However, in our antibody screening, NCAM1 was not detected as a hit (data not shown). 
Further, because the differentiation cultures from hESCs/iPSCs contain undifferentiated cells and non-renal lin-
eage cells and because NCAM1 is also expressed in non-renal tissues, such as neural tissues38, heart39 and skel-
etal muscle40, it may be difficult to use NCAM1 as an isolation marker for renal progenitors differentiated from 
hESCs/iPSCs.
AKI is directly related to patients’ short-term and long-term morbidity and mortality41–43. Especially, kidney 
fibrosis after AKI is one of the risk factors for progression to chronic kidney disease (CKD)18. We found that the 
hiPSC-derived renal progenitor cells isolated with the combination of cell surface markers established in this 
study prevented renal fibrosis after AKI induced by I/R injury in mice. One report showed that renal progenitor 
cells derived from hiPSCs ameliorated AKI induced by cisplatin administration44. However, because that study 
did not isolate renal progenitor cells, the cells transplanted may contain other lineage cells and undifferentiated 
cells. The isolation method of hiPSC-derived renal progenitor cells without genetic modification of the hiPSCs 
may give a substantial advantage in future cell therapies and disease modeling using patient-derived hiPSCs. 
However, we still have some issues to overcome before clinical applications. First, we need to develop long-term 
expansion cultures to obtain a large number of cells for use in the transplantation therapy, because of the low 
induction rate of OSR1+SIX2+ cells from hiPSCs. In addition, we have not yet demonstrated the therapeutic 
effects of cell therapy using hiPSC-derived renal progenitors for CKD mouse models. Future studies should 
address these issues toward clinical applications.
In conclusion, we identified the combination of four cell surface markers, CD9−CD140a+CD140b+CD271+, 
that enriches OSR1+SIX2+ renal progenitor cells at an efficiency above 60%. These isolated renal progenitor cells 
ameliorated AKI in mice. The isolation method established in this study may provide a tool that contributes to the 
development of hiPSC-based cell therapy and disease modeling against kidney diseases.
Materials and Methods
Cell Culture. The use of hiPSCs was approved by the Ethics Committee of Kyoto University, and informed 
consent was obtained from all donor subjects from which hiPSC lines were generated in accordance with the 
Declaration of Helsinki. Cell cultures were performed as previously described15,45. Four hiPSC lines: 201B746, 
3D45 (an OSR1-GFP knock-in hiPSC line generated from 201B745), 4A6 (an OSR1-GFP/SIX2-tdTomato 
knock-in hiPSC line generated from 3D4515) and 585A116 were maintained on feeder layers of mitomycin 
C-treated mouse embryonic fibroblasts (Oriental Yeast, Tokyo, Japan) or mouse SNL feeder cells with Primate 
ES medium (ReproCELL, Kanagawa, Japan) supplemented with 500 U/ml penicillin/streptomycin (PS; Thermo 
Fisher Scientific, Waltham, MA, USA) and 4 or 5 ng/ml recombinant human basic fibroblast growth factor (FGF; 
Wako, Osaka, Japan). hiPSCs were passaged at a split ratio of 1:3–1:6 every three to seven days by dissociation 
with CTK solution consisting of 0.25% trypsin (Thermo Fisher Scientific), 0.1% collagenase IV (Thermo Fisher 
Scientific), 20% Knockout serum replacement (KSR; Thermo Fisher Scientific) and 1 mM CaCl2 in PBS. hiPSCs 
were routinely examined for mycoplasma contamination.
Differentiation Protocol. Embryoid body (EB)-based differentiation was performed as previously 
described15. hiPSCs at 70–80% confluency were dissociated with CTK solution, scraped off with a cell scraper and 
plated into 0.1% or 0.2% gelatin-coated 6 cm dishes with EB medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 + Glutamax (Thermo Fisher Scientific) supplemented with 0.1 mM non-essential amino 
acids (Thermo Fisher Scientific), 1,000 U/ml PS, 55 µM 2-mercaptoethanol (Thermo Fisher Scientific) and 20% 
KSR to remove the feeder cells.
After 1.5–2 h of incubation, the cells were transferred into 35 mm low attachment dishes (SUMITOMO 
BAKELITE, Tokyo, Japan) or low attachment 6-well plates (Corning, Corning, NY, USA) containing Stage 1 
medium (DMEM/F12 + Glutamax supplemented with 500 U/ml PS and 2% fetal bovine serum (FBS, Biosera, 
Kansas City, MO, USA)) in the presence of 100 ng/ml recombinant human/mouse/rat activin A (R&D Systems, 
Minneapolis, MN, USA), 1 µM CHIR99021 (Axon Medchem, Groningen, Netherlands) and 10 µM Y-27632 
(Abcam Biochemicals, Cambridge, MA, USA) to form EBs. After 48 h from the beginning of the differentiation 
induction (day 3), EBs were plated into 24-well plates coated with Synthemax II (Corning). The medium was 
changed to Stage 2 medium (DMEM/F12 + Glutamax containing 0.1 mM non-essential amino acids, 500 U/ml 
PS, 55 µM 2-mercaptoethanol and 10% KSR) supplemented with 100 ng/ml recombinant human bone morphoge-
netic protein (BMP)7 (R&D Systems) and 1 µM CHIR99021 to commit the cells to the IM. On day 6, the medium 
was switched to Stage 2 medium supplemented with 1 µM TTNPB (Santa Cruz Biotechnology, Dallas, TX, USA) 
and 5 ng/ml transforming growth factor (TGF)-β1 (Peprotech, Rocky Hill, NJ, USA). On day 8, the medium was 
refreshed with new medium containing the same factors. On day 11, the cells were treated with Stage 2 medium 
supplemented with 5 ng/ml TGF-β1 and 0.5 µM dorsomorphin homologue (DMH)1 (Tocris Bioscience, Bristol, 
UK) to induce renal progenitor cells. Subsequently, the medium was replaced every three days.
585A1 cells were differentiated into renal progenitors by modifying another previously reported method12. 
In brief, dissociated hiPSCs were plated into U-shaped bottom low adhesion 96-well plates (SUMITOMO 
BAKELITE) at a density of 1.0 × 104 cells/well containing DMEM/F12 medium (Thermo Fisher Scientific), 2% 
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B27 without retinoic acid (Thermo Fisher Scientific), 0.1 mM non-essential amino acids, 1,000 U/ml PS, 90 µM 
2-mercaptoethanol and 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA; hereafter called basal medium) 
supplemented with 10 µM Y-27632 and 0.5 ng/ml BMP4 (R&D Systems). After 24 h (on day 2), the medium 
was changed to basal medium supplemented with 1 ng/ml recombinant human/mouse/rat activin A and 20 ng/
ml recombinant human basic FGF. After 48 h (on day 4), the medium was changed to basal medium supple-
mented with 1 ng/ml BMP4, 10 µM CHIR99021 and 10 µM Y-27632. On day 10, the aggregates were treated 
with basal medium supplemented with 10 ng/ml recombinant human/mouse/rat activin A, 3 ng/ml BMP4, 3 µM 
CHIR99021, 0.1 µM retinoic acid (Sigma-Aldrich) and 10 µM Y-27632. On day 12, the medium was switched to 
basal medium supplemented with 1 µM CHIR99021, 5 ng/ml FGF9 (Peprotech) and 10 µM Y-27632.
Antibody Screening. Comprehensive analysis of cell surface markers for the differentiated cells around 
culture day 28 was performed with BD Lyoplate™ Screening Panels (BD Biosciences, Franklin Lakes, NJ, USA) 
by flow cytometry. Immunostaining and analysis were performed according to the manufacturer’s protocol.
Flow Cytometry. The cells were treated with Accumax (Innovative Cell Technologies, San Diego, CA, USA) 
for 20 min at 37 °C and dissociated by pipetting. Dead cells were distinguished by 7-Amino-Actinomycin D 
(7AAD; 1:20; TONBO biosciences, Tucson, AZ, USA) or Hoechst 33342 (1:2,000; Thermo Fisher Scientific) and 
excluded from the analyses. Then, the cells were stained at a concentration of 1.0 × 106 cells/ml with monoclonal 
antibodies or isotype controls in Brilliant Stain Buffer (BD Biosciences). The cells were analyzed and sorted using 
a FACS Aria II cell sorter (BD Biosciences). The isolated cells were collected in Stage 2 medium containing 10 µM 
Y-27632. The data were analyzed using FACS Diva (BD Biosciences) software programs. Details of the antibodies 
used in this study are shown in Table S3.
Medium Conditioned by UB Cells (UBCs). UBC-conditioned medium was generated as previously 
reported15. UBCs (a kind gift from Drs. Sakurai and Barasch)47 were cultured with minimal essential media 
(MEM; Thermo Fisher Scientific) supplemented with 10% FBS. To obtain UBC-conditioned medium, cells at 
80% confluency were washed with PBS, and the medium was replaced with Stage 2 medium. After three days of 
incubation, the conditioned medium was filtered through 0.22 µm filters before use.
Organ Culture. Tubule-like structures were generated using previously reported methods15,17. To 
form cellular aggregates, CD9−CD140a+CD140b+CD271+ cells on day 28 were replated in spindle-shaped 
bottom low adhesion 96-well plates (SUMITOMO BAKELITE) at a density of 1.0 × 105 cells/well with 
UBC-conditioned medium supplemented with 50 ng/ml BMP7 and 10 μM Y-27632. After 24 h of incubation 
(day 2), the medium was changed to UBC-conditioned medium supplemented with 50 ng/ml BMP7, 0.5 μM 
6-bromoindirubin-3′-oxime (BIO; Sigma-Aldrich) and 10 μM Y-27632. On day 3, the aggregates were transferred 
onto transwell inserts (Corning) with KR5 medium (DMEM/F12 + Glutamax containing 0.1 mM non-essential 
amino acids, 500 U/ml PS, 55 µM 2-mercaptoethanol and 5% KSR) in the presence of 4 µM CHIR99021 and 200 
ng/ml FGF2 (Peprotech). After 2 days of culture (day 5), the medium was refreshed with KR5 medium, and the 
aggregates were cultured for an additional 8 days.
Transplantation. All animal experiments were approved by the CiRA Animal Experiment Committee and 
conducted in accordance with the institutional guidelines. The cells for transplantation were prepared using a 
modified version of a previously reported method15. In brief, CD9−CD140a+CD140b+CD271+ cells on day 28 
isolated by flow cytometry sorting were replated into V-shaped bottom low adhesion 96-well plates (SUMITOMO 
BAKELITE) at a density of 1.0 × 105 cells/well and treated with the same UBC-conditioned medium containing 
BMP7, BIO and Y-27632 as described above for 2 days. After washing the cells with saline to remove the media, 
16 aggregates (approximately 1.6 × 106 cells) of CD9−CD140a+CD140b+CD271+ cells were transplanted into the 
kidney subcapsules of immunodeficient mice (NOD.CB17-Prkdcscid/J) with AKI.
The mouse AKI models induced by ischemia/reperfusion (I/R) injury were generated as described previ-
ously15,48–50. Briefly, six-week-old male immunodeficient mice were anaesthetized by isoflurane and maintained 
at 37 °C. One week after right nephrectomy, the left renal artery was clamped for 31 min with an atraumatic 
microvascular clamp (Natsume Seisakusho, Osaka, Japan). After removing the clamp, the cellular aggregates were 
transplanted into the kidney subcapsules, while the control mice received a saline injection.
Peripheral blood tests were performed every two days for blood urea nitrogen (BUN) and serum creatinine 
(Cre) levels using DRI-CHEM 7000VZ (Fuji film, Tokyo, Japan). Twelve days later, the mice were sacrificed, and 
kidney tissues were collected for analysis.
Renal Histopathology. After being removed from the host mice, the kidneys were fixed in 10% neutral 
buffered formalin and embedded in paraffin. The paraffin blocks were sectioned at 3 µm, and the sections were 
stained with hematoxylin and eosin (HE), periodic acid-Schiff (PAS), Masson’s trichrome (MT) and Sirius red 
(SR) stainings. For histological assessments, at least 10 non-overlapping fields in one entire section of each kidney 
sample were randomly chosen and examined using a 20x objective. The renal morphologic changes were assessed 
based on well-established methods for AKI51–53. Briefly, four changes were examined: 1) tubular necrosis, 2) uri-
nary casts, 3) tubular dilatation and 4) loss of tubular borders on a scale of 0 to 2 (0, none; 1/2, minimal; 1, mild; 
1 1/2, moderate; and 2, marked). For objective assessments, these examinations were performed by the CMIC 
Bioresearch Center Co., Ltd. (Tokyo, Japan). To measure the positive areas by MT and SR stainings and α-SMA 
immunostaining, 9–16 non-overlapping fields in one entire section of each kidney sample were randomly chosen, 
and the measurements were performed using BZ analyzer in Hybrid Cell Count mode (Keyence).
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Statistical analysis. Statistics are presented as means ± standard error (SE) or 95% confidence intervals 
(CI). We applied the student’s t test for comparisons between two groups. Changes in BUN and Cre at each time 
point from baseline are described by the generalized linear mixed model to obtain point estimates and 95% CIs. 
The model included treatment group, time, and treatment-by-time interaction as factors and random intercept 
for each subject, and the model parameters were estimated by restricted maximum likelihood. The correlation 
structure was assumed as unstructured, and the Toeplitz, autoregressive, or compound-symmetry structures were 
used in order if convergence was not obtained. All statistical analyses were performed using SAS software version 
9.4. (SAS Institute Inc, Cary, NC, USA).
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